A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients
暂无分享,去创建一个
Ewout W. Steyerberg | J. Dik F. Habbema | Merel R. van Dijk | J. Habbema | E. Steyerberg | M. V. Dijk | J. Habbema | J. D. F. Habbema | M. van Dijk
[1] J Schleicher,et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Paul J Catalano,et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors , 2003, Cancer.
[3] E W Steyerberg,et al. Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning , 2004, British Journal of Cancer.
[4] R Sylvester,et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] B. Kempf,et al. First-Line High-Dose Chemotherapy for ’Poor Risk’ Metastatic Non-Seminomatous Testicular Germ Cell Tumors , 1998, Oncology Research and Treatment.
[6] Alberto Redaelli,et al. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. , 2004, Cancer treatment reviews.
[7] Alan Horwich,et al. Testicular germ-cell cancer , 2006, The Lancet.
[8] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[9] D. G. Altman,et al. Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.
[10] C. Bokemeyer,et al. Therapy‐related malignancies following treatment of germ cell cancer , 1999, International journal of cancer.
[11] R H Begent,et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Ewout W Steyerberg,et al. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. , 2006, European journal of cancer.
[13] D J van Veldhuisen,et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Tammy O. Tengs,et al. One thousand health-related quality-of-life estimates. , 2000, Medical care.
[15] C. Bokemeyer,et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Andrew J Vickers,et al. Selecting patients for randomized trials: a systematic approach based on risk group , 2006, Trials.
[17] C. Meisner,et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Wilkinson,et al. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Tabernero,et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG) , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Edward L Spitznagel,et al. Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.
[21] G. Bosl,et al. The future of therapy for nonseminomatous germ cell tumors. , 2002, Chest surgery clinics of North America.
[22] Les M Irwig,et al. An evidence based approach to individualising treatment , 1995, BMJ.
[23] H S Koops,et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era , 2001, Cancer.
[24] Ruth Ladenstein,et al. High-dose chemotherapy for solid tumors: results of the EBMT. , 2002, Critical reviews in oncology/hematology.
[25] Harald J. Hoekstra,et al. Sexual Functioning After Treatment for Testicular Cancer—Review and Meta-Analysis of 36 Empirical Studies Between 1975–2000 , 2001, Archives of sexual behavior.
[26] J Schleicher,et al. Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer , 2002, British Journal of Cancer.
[27] M Mazumdar,et al. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Ewout W Steyerberg,et al. Survival estimates of a prognostic classification depended more on year of treatment than on imputation of missing values. , 2006, Journal of clinical epidemiology.
[29] Leslie L Robison,et al. Trends in leukemia incidence and survival in the United States (1973–1998) , 2003, Cancer.
[30] J. Moul,et al. Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors , 2000, European Urology.
[31] L Collette,et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) , 2005, British Journal of Cancer.
[32] G. Morgan,et al. Autologous stem cell transplantation for malignancy: a systematic review of the literature. , 2000, Clinical and laboratory haematology.
[33] Richard Sylvester,et al. International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .
[34] D P Dearnaley,et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] C. Bokemeyer,et al. Long-term effects on sexual function and fertility after treatment of testicular cancer , 1999, British Journal of Cancer.
[36] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[37] Sonneveld,et al. The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996 , 1999, BJU international.